RESUMEN
Haematococcus pluvialis is a green alga that can accumulate high astaxanthin content, a commercially demanding market keto food. Due to its high predicted market value of about 3.4 billion USD in 2027, it is essential to increase its production. Therefore, it is crucial to understand the genetic mechanism and gene expressions profile during astaxanthin synthesis. The effect of poly- and mono-chromatic light of different wavelengths and different intensities have shown to influence the gene expression towards astaxanthin production. This includes transcriptomic gene analysis in H. pluvialis underneath different levels of illumination stress. This review has placed the most recent data on the effects of light on bioastaxanthin production in the context of previous studies, which were more focused on the biochemical and physiological sides. Doing so, it contributes to delineate new ways along the biotechnological process with the aim to increase bioastaxanthin production while decreasing production costs.
Asunto(s)
Chlorophyceae , Chlorophyta , Chlorophyta/genética , Transcriptoma , XantófilasRESUMEN
The development of antidepressants requires simple rodent behavioral tests for initial screening before undertaking more complex preclinical tests and clinical evaluation. Presented in the unit are two widely used screening tests used for antidepressants, the forced swim (also termed behavioral despair) test in the rat and mouse, and the tail suspension test in the mouse. These tests have good predictive validity and allow rapid and economical detection of substances with potential antidepressant-like activity. The behavioral despair and the tail suspension tests are based on the same principle: measurement of the duration of immobility when rodents are exposed to an inescapable situation. The majority of clinically used antidepressants decrease the duration of immobility. Antidepressants also increase the latency to immobility, and this additional measure can increase the sensitivity of the behavioral despair test in the mouse for certain classes of antidepressant. Testing of new substances in the behavioral despair and tail suspension tests allows a simple assessment of their potential antidepressant activity by the measurement of their effect on immobility.
Asunto(s)
Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/fisiopatología , Modelos Animales de Enfermedad , Pruebas Neuropsicológicas/normas , Restricción Física/psicología , Natación/psicología , Animales , Antidepresivos/farmacología , Conducta Animal/fisiología , Trastorno Depresivo/diagnóstico , Evaluación Preclínica de Medicamentos/métodos , Etología/métodos , Desamparo Adquirido , Vivienda para Animales/normas , Masculino , Ratones , Ratas , Ratas Wistar , Restricción Física/efectos adversos , Natación/fisiologíaRESUMEN
In this study, we investigated the effect of a high n-3 fatty acid diet (eicosapentaenoic and docosahexaenoic acids) in Zucker obese and lean rats on blood pressure in association with physiological parameters, serum biochemistry and oxidative stress analysis. After 150 days of treatment, dietary fish oil supplementation in Zucker obese rats (9 months of age) reduces bodyweight gain and serum triglyceridemia and nitrite levels, increases serum glucose and angiotensin converting enzyme activity, but does not alter blood pressure, cholesterol levels and serum markers of oxidative stress (malondialdehyde, glutathione), compared to the Zucker rats fed control diet. According to these results, we can consider that after 150 days of treatment, fish oil is not enough to regulate parameters involved in the metabolic syndrome, such as cholesterolemia and blood pressure, in a 9 month-old genetically type-2 diabetes rat.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/fisiopatología , Grasas Insaturadas en la Dieta/administración & dosificación , Aceites de Pescado/administración & dosificación , Estrés Oxidativo , Animales , Biomarcadores/sangre , Diabetes Mellitus Tipo 2/genética , Grasas Insaturadas en la Dieta/farmacología , Aceites de Pescado/farmacología , Glutatión/metabolismo , Masculino , Obesidad/metabolismo , Ratas , Ratas ZuckerRESUMEN
The development of antidepressants requires simple rodent behavioral tests for initial screening before undertaking more complex preclinical tests and clinical evaluation. Presented in the unit are two widely used screening tests used for antidepressants, the forced swim (also termed behavioral despair) test in the rat and mouse, and the tail suspension test in the mouse. These tests have good predictive validity and allow rapid and economical detection of substances with potential antidepressant-like activity. The behavioral despair and the tail suspension tests are based on the same principle: measurement of the duration of immobility when rodents are exposed to an inescapable situation. The majority of clinically used antidepressants decrease the duration of immobility. Antidepressants also increase the latency to immobility, and this additional measure can increase the sensitivity of the behavioral despair test in the mouse for certain classes of antidepressant. Testing of new substances in the behavioral despair and tail suspension tests allows a simple assessment of their potential antidepressant activity by the measurement of their effect on immobility.
Asunto(s)
Trastorno Depresivo/etiología , Modelos Animales de Enfermedad , Suspensión Trasera/psicología , Pruebas Neuropsicológicas , Estrés Psicológico/psicología , Natación/psicología , Animales , Antidepresivos/administración & dosificación , Trastorno Depresivo/tratamiento farmacológico , Evaluación Preclínica de Medicamentos/métodos , Masculino , Ratones , Ratas , Ratas WistarRESUMEN
PURPOSE: The objective of this study was to characterize the antiseizure and safety profiles of ABT-769 [(R)-N-(2 amino-2-oxoethyl)spiro[2,5]octane-1-carboxamide]. METHODS: ABT-769 was tested for protection against maximal electroshock and pentylenetetrazol-induced seizures in the mouse and for suppression of electrically kindled amygdala seizures and spontaneous absence-like seizures in the rat. The central nervous system safety profile was evaluated by using tests of motor coordination and inhibitory avoidance. The potential for liver toxicity was assessed in vitro by using a mitochondrial fatty acid beta-oxidation assay. Teratogenic potential was assessed in the mouse. RESULTS: ABT-769 blocked maximal electroshock, subcutaneous pentylenetetrazol and intravenous pentylenetetrazol-induced seizures with median effective dose (ED50) values of 0.25, 0.38, and 0.11 mmol/kg, p.o., respectively. No tolerance was evident in the intravenous pentylenetetrazol test after twice-daily dosing of ABT-769 (0.3 mmol/kg, p.o.) for 4 days. ABT-769 blocked absence-like spike-wave discharge (ED50, 0.15 mmol/kg, p.o.) and shortened the cortical and amygdala afterdischarge duration of kindled seizures (1 and 3 mmol/kg, p.o.). The protective indices (ED50 rotorod impairment/ED50 seizure protection) were 4.8, 3.2, and 10.9 in the maximal electroshock, subcutaneous pentylenetetrazol and intravenous pentylenetetrazol seizure tests, respectively. ABT-769 did not affect inhibitory avoidance performance (0.1-1 mmol/kg, p.o.). ABT-769 did not affect mitochondrial fatty acid beta-oxidation or induce neural tube defects. CONCLUSIONS: ABT-769 is an efficacious antiseizure agent in animal models of convulsive and nonconvulsive epilepsy and has a favorable safety profile. ABT-769 has a broad-spectrum profile like that of valproic acid. Its profile is clearly different from those of carbamazepine, phenytoin, lamotrigine, topiramate, vigabatrin, and tiagabine.
Asunto(s)
Anticonvulsivantes/farmacología , Anticonvulsivantes/toxicidad , Conducta Animal/efectos de los fármacos , Epilepsia/prevención & control , Ácido Valproico/análogos & derivados , Ácido Valproico/farmacología , Anomalías Inducidas por Medicamentos/epidemiología , Amígdala del Cerebelo/efectos de los fármacos , Amígdala del Cerebelo/fisiopatología , Animales , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Electrochoque , Epilepsia/inducido químicamente , Epilepsia/metabolismo , Epilepsia Tipo Ausencia/inducido químicamente , Epilepsia Tipo Ausencia/metabolismo , Epilepsia Tipo Ausencia/prevención & control , Humanos , Inyecciones Intravenosas , Inyecciones Subcutáneas , Excitación Neurológica/efectos de los fármacos , Excitación Neurológica/metabolismo , Excitación Neurológica/fisiología , Masculino , Ratones , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , Pentilenotetrazol/administración & dosificación , Ratas , Ratas Wistar , Especificidad de la Especie , Compuestos de Espiro/farmacología , Compuestos de Espiro/toxicidad , Ácido Valproico/toxicidadRESUMEN
The Irwin observation test is commonly used to evaluate the effects of a new substance on behavior and physiological function. The results of the Irwin test are used to determine potential toxicity and to select doses for specific therapeutic activity. The Irwin test can also be used in a safety approach for detecting untoward effects of a new compound on general behavior and for evaluating its acute neurotoxicity. In particular, data obtained in the Irwin Test can help to determine the dose range to be tested in other safety tests. Furthermore, the Irwin Test can furnish a first but pertinent orientation towards a specific therapeutic indication, a specific mechanism of action or a specific physiological function.
Asunto(s)
Conducta Animal/efectos de los fármacos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/fisiopatología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/psicología , Enfermedades del Sistema Nervioso/inducido químicamente , Psicofarmacología/métodos , Psicofisiología/métodos , Crianza de Animales Domésticos/métodos , Animales , Evaluación Preclínica de Medicamentos/métodos , Masculino , Actividad Motora/efectos de los fármacos , Enfermedades del Sistema Nervioso/fisiopatología , Ratas , Ratas WistarRESUMEN
These studies examined the influence of the selective 5-hydroxytryptamine (serotonin) (5-HT)(1A) receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] upon cholinergic transmission and cognitive function in rodents. In the absence of acetylcholinesterase inhibitors, S15535 dose-dependently (0.04-5.0 mg/kg s.c.) elevated dialysis levels of acetylcholine in the frontal cortex and dorsal hippocampus of freely moving rats. In the cortex, the selective 5-HT(1A) receptor antagonist WAY100,635 [(N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclo-hexanecarboxamide) fumarate] dose-dependently (0.0025-0.63) blocked this action of S15535. By contrast, in dorsal hippocampus, WAY100,635 mimicked the induction of acetylcholine release by S15535. In a social recognition paradigm, S15535 dose-dependently (0.16-10.0) improved retention, an action blocked by WAY100,635 (0.16), which was ineffective alone. Furthermore, S15535 dose-dependently (0.04-2.5) and WAY100,635 reversibly abolished amnesic properties of the muscarinic antagonist scopolamine (0.63) in this procedure. Cognitive deficits provoked by scopolamine in autoshaping and Morris water-maze procedures were likewise blocked by S15535 at doses of 0.63 to 10.0 and 0.16 to 2.5, respectively. In a two-platform spatial discrimination task, in which S15535 similarly abrogates cognitive deficits elicited by scopolamine, injection of S15535 (1.0 and 10.0 microg) into dorsal hippocampus blocked amnesic effects of the 5-HT(1A) agonist 8-hydroxy-2-dipropylaminotetralin (0.5 microg). Finally, S15535 (0.16-0.63) improved performance in a spatial, delayed nonmatching to sample model in mice, and in an operant delayed nonmatching to sample model in old rats, S15535 (1.25-5.0 mg/kg p.o.) increased response accuracy and reduced latency to respond. In conclusion, S15535 reinforces frontocortical and hippocampal release of acetylcholine and displays a broad-based pattern of procognitive properties. Its actions involve both blockade of postsynaptic 5-HT(1A) receptors and engagement of 5-HT(1A) autoreceptors.
Asunto(s)
Piperazinas/farmacología , Receptor de Serotonina 5-HT1A/metabolismo , Agonistas de Receptores de Serotonina/farmacología , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Acetilcolina/metabolismo , Envejecimiento/fisiología , Amnesia/inducido químicamente , Animales , Diálisis , Aprendizaje Discriminativo/efectos de los fármacos , Interacciones Farmacológicas , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Memoria/efectos de los fármacos , Memoria/fisiología , Ratones , Ratones Endogámicos C57BL , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Ratas , Ratas Wistar , Reconocimiento en Psicología/efectos de los fármacos , Escopolamina/farmacología , Conducta Espacial/efectos de los fármacos , Conducta Espacial/fisiologíaRESUMEN
Conditioned place preference is a behavioral model currently used to measure the rewarding properties induced by the administration of a drug. In this paradigm, the rewarding properties of a compound are associated with the particular characteristics of a given environment. Advantages of this test are the absence of any instrumental learning and the possibility of evaluating reinforcing effects in the absence of the test substance. Due to the recent availability of multiple lines of genetically modified mice, this unit has been updated to include procedures for testing place preference in both rats and mice. Details are also provided for evaluating drug effects using this procedure.
Asunto(s)
Condicionamiento Psicológico/efectos de los fármacos , Motivación/efectos de los fármacos , Recompensa , Crianza de Animales Domésticos , Animales , Ambiente Controlado , Masculino , Ratones , Preparaciones Farmacéuticas , Ratas , Ratas Wistar , Refuerzo en Psicología , Manejo de EspecímenesRESUMEN
Conditioned place preference is a behavioral model currently used to measure the rewarding properties induced by the administration of a drug. In this paradigm, the rewarding properties of a compound are associated with the particular characteristics of a given environment. Due to the recent availability of multiple lines of genetically modified mice, this unit includes procedures for testing place preference in both rats and mice.
Asunto(s)
Ciencias de la Conducta/métodos , Investigación Biomédica/métodos , Condicionamiento Psicológico , Ambiente , Neurociencias/métodos , Roedores/psicología , Animales , Masculino , Ratones/psicología , Ratones Endogámicos C57BL , Motivación , Preparaciones Farmacéuticas , Ratas/psicología , Ratas Wistar , RecompensaRESUMEN
International requirements for central nervous system (CNS) safety pharmacology are reviewed. Procedures for initial CNS safety screening (core battery studies) can be conducted from the beginning of the drug discovery process, but at latest before first studies in man. They should include assessment of general behaviour, locomotor activity and motor coordination, but can also include studies of pain sensitivity, convulsive threshold and interaction with hypnotics. Follow-up studies, to be conducted later in the drug development process but before product approval, cover assessment of higher cognitive function, electroencephalogram (EEG) and drug dependence/abuse liability. Procedures for assessing cognitive function can include, in order of complexity, passive avoidance, Morris and radial mazes and operant behaviour tasks (delayed alternation, repeated acquisition). EEG can include the quantified EEG (QEEG) and studies of the sleep/wakefulness cycle. Drug dependence/abuse procedures can include precipitated and nonprecipitated withdrawal (drug dependence), and place preference, drug discrimination and self-administration (drug abuse). In contrast to core battery CNS procedures, conducted exclusively in rodents, follow-up studies can include higher species, in particular primates.